Der Einfluss des neuartigen Aldosteronantagonisten MYO 302 auf Gewichtsverlauf, Körperzusammensetzung, Spontanaktivität und Herzfunktion im Rattenmodell der Tumor-Kachexie

The impact of the new aldosterone antagonist MYO 302 on the development of body weight, on body composition, on spontaneous activity and cardiac function in a rat model of cancer cachexia Cachexia combined with a cancer disease represents a poor survival prognosis. So far no effective therapy to treat tumor associated cachexia was discovered. This study shows the effect of a new aldosterone antagonist, MYO 302, in a rat model of cancer cachexia. The rats were inoculated with Yoshida AH-130-Hepatoma cells into the peritoneal cavity to develop a liquid tumor. The treatment with MYO 302 shows positive effects in treated rats in comparison to untreated rats, depending on the dose of MYO 302. The animals under treatment with the dose of 1mg/kg/d MYO 302 showed the highest survival rate. There was less weight loss of the white adipose tissue than in untreated rats. The treatment shows no effect on the mass of the muscle weight. The treatment of tumor bearing rats with MYO 302 is, depending on the dose, suitable to increase the survival rate and to attenuate the cancer cachexia. This leads to positive impact on the disease. Further studies are necessary to find the optimal therapeutic dose.